# Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC

> **NCT06694350** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab+Flutamide

## Key facts

- **NCT ID:** NCT06694350
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06694350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06694350, "Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06694350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*